Postoperative combined radiotherapy (RT) and chemotherapy (CT) in patients with resected gastric adenocarcinoma


Serval ID
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Postoperative combined radiotherapy (RT) and chemotherapy (CT) in patients with resected gastric adenocarcinoma
Title of the conference
12th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO)
Khanfir K., Zouhair A., Bieri S., Montemurro M., Anchisi S., Zenhäusern R., Cornu P., Pachoud M., Mirimanoff RO., Ozsahin M.
CHUV Lausanne, April 10-12, 2008
Publication state
Issued date
Objective : Postoperative adjuvant CT combined to RT remains the standard of care for high-risk patients with adenocarcinoma of the stomach (AS) or gastroesophageal junction (GEJ), not receiving any neoadjuvant CT. Herein, we assess the outcome of patients treated with the Intergroup (INT-0116) schema.
Materials and Methods : From 2001-2006, 25 patients with high-risk AS or GEJ were treated. Twenty-eight percent of the patients had Portuguese origin. Eighty-eight percent of the patients had pN1-N2, and 28% pT3 tumors. Treatment consisted of postoperative CT/RT (5FU-leucovorin) using 45-Gy 3D
conformal RT or IMRT in all patients.
Results : With a median follow-up of 29 months, 12 patients are alive without disease. The median overall survival (OS) was 41 months. The 3-year OS and disease-free survival (DFS) rates were 61% and 45%, respectively. The 3-year locoregional control rate was 57%. In univariate analyses, the best factors influencing the outcome were good performance status (PS) and
Portuguese origin. Only PS emerged as an independent factor in multivariate analysis. There was no toxic death. Tolerance was acceptable (1 patient with grade 3 leukopenia, and 3 patients with grade 3 gastrointestinal toxicity).
Conclusions : Adjuvant CT/RT is tolerated, and offers a long-term survival with acceptable morbidity in selected patients with AS or GEJ.
Create date
15/04/2009 8:17
Last modification date
20/08/2019 14:37
Usage data